Ziprasidone
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Ziprasidone: Trichotillomania
One-Sentence Summary
Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors. The TxGNN model predicts it may be useful for trichotillomania (score 0.9983). No clinical trials or publications on this disease were found in the data compiled for this report, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Trichotillomania |
| TxGNN Prediction Score | 0.9983 |
| Evidence Level | L5 (model prediction only) |
| India Market Status | Listed in a compiled Indian medicine price dataset (14 of 14) – CDSCO approval status is not included in this data |
| Number of Listed Products | 14 (valid: 14) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for ziprasidone is not available in the data compiled for this report. Ziprasidone is a member of the atypical antipsychotic class, which acts on D2 and 5-HT2A receptors.
Trichotillomania is a repetitive, compulsive hair-pulling disorder that sits in the obsessive-compulsive spectrum. Dopamine and serotonin signalling are thought to be involved in this group of conditions, and antipsychotics have been explored in related disorders. This is a plausible hypothesis, but no data supplied here tests it for trichotillomania.
The prediction score is high, but the evidence base is empty. No registered trials, no publications and no preclinical studies were supplied. The prediction should therefore be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Ziprasidone is marketed in India. All 14 recorded licences are valid single-ingredient products, and none are cancelled. Five main authorizations are listed below. The licence records carry no approved-indication text.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 248770 | Zipra 20mg Capsule | Strip of 10 capsules | Zydus Cadila |
| 251150 | Zipris 20mg Capsule | Strip of 10 capsules | Sunrise Remedies Pvt Ltd |
| 249523 | Zipral 40mg Capsule | Strip of 10 capsules | Lifecare Neuro Products Ltd |
| 7383 | Azona 40mg Capsule | Strip of 10 capsules | Torrent Pharmaceuticals Ltd |
| 248256 | Zipradep 80mg Tablet | Strip of 10 tablets | Emco Biotech |
Safety Considerations
- Conditions of concern: The data compiled for this report flags the following. This is not label text.
- Cardiac and rhythm conditions: long QT syndrome (including familial), torsades de pointes, sudden cardiac arrest, heart conduction disease, myocardial infarction, orthostatic hypotension.
- Metabolic conditions: diabetes mellitus, diabetic ketoacidosis, hyperglycemia, hyperlipidemia, obesity.
- Blood and organ conditions: neutropenia, agranulocytosis, liver failure, kidney disease.
- Neurological conditions: epilepsy, basal ganglia disease.
- Drug Interactions: 305 interactions are recorded. Major-level interactions include hydrocortisone, amphotericin B (including the lipid complex), bupropion and morphine. Moderate-level interactions include several diabetes medicines (metformin, pioglitazone, alogliptin, acarbose, albiglutide), famotidine, epinephrine and several anticholinergic agents (atropine, hyoscyamine, glycopyrronium).
Package insert warnings and contraindications were not captured. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but no trials or publications on trichotillomania were found, so the evidence level is L5. Ziprasidone is known to prolong the QT interval and has notable metabolic and interaction concerns. These risks are hard to justify without any supporting efficacy data.
To proceed, the following is needed:
- A systematic literature search for antipsychotic or serotonergic treatment in trichotillomania, and a comparison with established treatment options.
- Detailed mechanism-of-action data for ziprasidone.
- The package insert warnings and contraindications from the Indian licences.
- A cardiac (QTc) safety plan, with review of interacting medicines, if any clinical study is considered.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.